Cargando…

Prelamin A causes progeria through cell-extrinsic mechanisms and prevents cancer invasion

Defining the relationship between ageing and cancer is a crucial but challenging task. Mice deficient in Zmpste24, a metalloproteinase mutated in human progeria and involved in nuclear prelamin A maturation, recapitulate multiple features of ageing. However, their short lifespan and serious cell-int...

Descripción completa

Detalles Bibliográficos
Autores principales: de la Rosa, Jorge, Freije, José M. P., Cabanillas, Rubén, Osorio, Fernando G., Fraga, Mario F., Fernández-García, M. Soledad, Rad, Roland, Fanjul, Víctor, Ugalde, Alejandro P., Liang, Qi, Prosser, Haydn M., Bradley, Allan, Cadiñanos, Juan, López-Otín, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3758871/
https://www.ncbi.nlm.nih.gov/pubmed/23917225
http://dx.doi.org/10.1038/ncomms3268
Descripción
Sumario:Defining the relationship between ageing and cancer is a crucial but challenging task. Mice deficient in Zmpste24, a metalloproteinase mutated in human progeria and involved in nuclear prelamin A maturation, recapitulate multiple features of ageing. However, their short lifespan and serious cell-intrinsic and cell-extrinsic alterations restrict the application and interpretation of carcinogenesis protocols. Here we present Zmpste24 mosaic mice that lack these limitations. Zmpste24 mosaic mice develop normally and keep similar proportions of Zmpste24-deficient (prelamin A accumulating) and Zmpste24-proficient (mature lamin A containing) cells throughout life, revealing that cell-extrinsic mechanisms are preeminent for progeria development. Moreover, prelamin A accumulation does not impair tumour initiation and growth, but it decreases the incidence of infiltrating oral carcinomas. Accordingly, silencing of ZMPSTE24 reduces human cancer cell invasiveness. Our results support the potential of cell-based and systemic therapies for progeria and highlight ZMPSTE24 as a new anticancer target.